You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Baxter
Boehringer Ingelheim
Colorcon
McKesson
Moodys
McKinsey

Last Updated: September 27, 2020

DrugPatentWatch Database Preview

Patent: 9,771,413

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,771,413
Title:Recombinant human antibodies for therapy and prevention of polyomavirus-related diseases
Abstract: Provided are novel human-derived antibodies specifically recognizing polyomavirus polypeptides, preferably capable of binding to polyomaviruses of the type of JC virus (JCV) and/or BK virus (BKV) as well as methods related thereto. Furthermore, assays and kits related to antibodies specific for polyomaviruses, polyomavirus VP1 and or polyomavirus VP1 Virus-Like Particles (VLPs), preferably of the type of JCV and/or BKV, are disclosed. The human-derived antibodies as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for polyomavirus targeted immunotherapy and diagnostics.
Inventor(s): Grimm; Jan (Dubendorf, CH), Martin; Roland (Zurich, CH), Combaluzier; Benoit (Urdorf, CH), Jelcic; Ivan (Zurich, CH)
Assignee: Neurimmune Holding AG (Schlieren, CH) University of Zurich (Zurich, CH)
Application Number:14/758,615
Patent Claims:see list of patent claims

Details for Patent 9,771,413

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 001 1997-11-26   Start Trial Neurimmune Holding AG (Schlieren, CH) University of Zurich (Zurich, CH) 2032-12-31 RX search
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 002 1997-11-26   Start Trial Neurimmune Holding AG (Schlieren, CH) University of Zurich (Zurich, CH) 2032-12-31 RX search
Centocor Inc REMICADE infliximab VIAL 103772 001 1998-08-24   Start Trial Neurimmune Holding AG (Schlieren, CH) University of Zurich (Zurich, CH) 2032-12-31 RX Orphan search
Genzyme CAMPATH alemtuzumab VIAL; INTRAVENOUS 103948 001 2001-05-07   Start Trial Neurimmune Holding AG (Schlieren, CH) University of Zurich (Zurich, CH) 2032-12-31 RX Orphan search
Genzyme CAMPATH alemtuzumab VIAL; INTRAVENOUS 103948 002 2001-05-07   Start Trial Neurimmune Holding AG (Schlieren, CH) University of Zurich (Zurich, CH) 2032-12-31 RX Orphan search
Genzyme LEMTRADA alemtuzumab INJECTABLE;INJECTION 103948 003 2001-05-07   Start Trial Neurimmune Holding AG (Schlieren, CH) University of Zurich (Zurich, CH) 2032-12-31 RX Orphan search
Biogen Idec TYSABRI natalizumab VIAL; SINGLE-USE 125104 001 2004-11-23   Start Trial Neurimmune Holding AG (Schlieren, CH) University of Zurich (Zurich, CH) 2032-12-31 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Baxter
Colorcon
Boehringer Ingelheim
AstraZeneca
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.